Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with nonmetastatic hormone-refractory prostate cancer (HRPC)

被引：0
|
作者：
Nelson, J. B.
Chin, J. L.
Love, W.
Schulman, C.
Sleep, D.
Qian, J.
Steinberg, J.
Hintzman, P.
Dawson, M.
Carducci, M.
机构：
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[2] London Hlth Sci Ctr, London, ON, Canada
[3] Urol Res Ctr, Burlington, ON, Canada
[4] Hop Erasme, Brussels, Belgium
[5] Abbott, Abbott Pk, IL USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5018
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Satraplatin significantly improves progression free survival (PFS) and pain control in patients with advanced hormone-refractory prostate cancer (HRPC): Preliminary results from the phase III sparc trial
    Sartor, Oliver
    Sternberg, Cora
    Witjes, J. Alfred
    Chatta, Gurkamal
    Vaughn, David
    Berry, William
    Lara, Primo, Jr.
    Nathan, Faith E.
    McKeam, Tom
    Petrylak, Daniel P.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 335 - 335
  • [42] A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer
    Stadler, WM
    Cao, DC
    Vogelzang, NJ
    Ryan, CW
    Hoving, K
    Wright, R
    Karrison, T
    Vokes, EE
    CLINICAL CANCER RESEARCH, 2004, 10 (10) : 3365 - 3370
  • [43] Phase II study of CC-4047 in patients (pts) with metastatic hormone-refractory prostate cancer (HRPC)
    Floissac, M
    Knight, R
    Levin, A
    Glode, LM
    Crawford, ED
    Amato, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 410S - 410S
  • [44] A retrospective analysis on 35 patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel
    Carlini, P.
    Felici, A.
    Ruggeri, E. M.
    Moscetti, L.
    Chilelli, M.
    Ciccarese, M.
    Pino, M. S.
    Cecere, F. L.
    Nuzzo, C.
    Sperduti, I
    Pollera, C. F.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [45] Gene profiling in transurethral resection samples of patients with hormone-refractory prostate cancer (HRPC).
    Stoss, O.
    Albers, P.
    Werther, M.
    Zielinsky, D.
    Jost, N.
    Rueschoff, J.
    Henkel, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 251S - 251S
  • [46] The use of bisphosphonates in men with hormone-refractory prostate cancer: A systematic review of randomized trials
    Berry, S
    Waldron, T
    Winquist, E
    Lukka, H
    RADIOTHERAPY AND ONCOLOGY, 2005, 76 : S36 - S36
  • [47] Role of quality of life in men with metastatic hormone-refractory prostate cancer: How does atrasentan influence quality of life?
    Cella, D
    Petrylak, DP
    Fishman, M
    Teigland, C
    Young, J
    Mulani, P
    EUROPEAN UROLOGY, 2006, 49 (05) : 781 - 789
  • [48] A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer
    Dreicer, R
    Kemp, JD
    Stegink, LD
    Cardillo, T
    Davis, CS
    Forest, PK
    See, WA
    CANCER INVESTIGATION, 1997, 15 (04) : 311 - 317
  • [49] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Goodin, S
    Rao, KV
    Kane, M
    Dave, N
    Capanna, T
    Doyle-Lindrud, S
    Engle, E
    Jin, LX
    Todd, M
    DiPaola, RS
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) : 199 - 204
  • [50] A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer
    Susan Goodin
    Kamakshi V. Rao
    Michael Kane
    Nisha Dave
    Terry Capanna
    Susan Doyle-Lindrud
    Elizabeth Engle
    Lixian Jin
    Mary Todd
    Robert S. DiPaola
    Cancer Chemotherapy and Pharmacology, 2005, 56 : 199 - 204
12345